2016 updated MASCC/ESMO consensus recommendations: Anticipatory nausea and vomiting in children and adults receiving chemotherapy
- 1.1k Downloads
We aimed to update the 2011 recommendations for the prevention and treatment of anticipatory nausea and vomiting in children and adults receiving chemotherapy.
The original systematic literature search was updated. Randomized studies were included in the evidence to support this guideline if they as follows: were primary studies published in a journal in full text (i.e., abstracts, letters, book chapters, and dissertations were excluded); published in English; evaluated an intervention for the prevention or treatment of anticipatory nausea and vomiting; reported the proportion of patients experiencing complete control of anticipatory nausea and vomiting consistently and; included at least ten participants per study arm for comparative studies and at least ten participants overall for noncomparative studies.
Eighty-eight new citations were identified. Of these, nine were brought to full-text screening; none met inclusion criteria. The guideline panel continues to recommend that anticipatory nausea and vomiting are best prevented through optimization of acute and delayed phase chemotherapy-induced nausea and vomiting control. Benzodiazepines and behavioral therapies, in particular progressive muscle relaxation training, systematic desensitization and hypnosis, continue to be recommended for the treatment of anticipatory nausea and vomiting.
No new information regarding interventions aimed at treating or preventing ANV that met criteria for inclusion in this systematic review was identified. The 2015 MASCC recommendations affirm the content of the 2009 MASCC recommendations for the prevention and treatment of anticipatory nausea and vomiting.
KeywordsAnticipatory nausea Anticipatory vomiting Adults Children Supportive care
The MASCC Anticipatory Nausea and Vomiting Guideline Development Panel is grateful to the Pediatric Oncology Group of Ontario (POGO) for granting permission to update the literature search undertaken for the Guideline for the Prevention and Treatment of Anticipatory Nausea and Vomiting Due to Chemotherapy in Pediatric Cancer Patients. The guidance of Dr. P.D. Robinson with respect to clinical practice guideline methods is acknowledged with thanks. The assistance of Ms. Mila Khanna is also gratefully acknowledged.
Disclosures: M. Aapro has received support from Helsinn; Tesaro; MSD Merck, and Roche. L.L. Dupuis has participated in research partially supported by Sea-Band Ltd. A. Molassiotis has received honoraria and support from MSD Merck; Helsinn; Tesaro; Norgine; and Acacia Pharma. I. Olver has received support from Tesaro. J. Roscoe has no disclosures to declare.
- 5.Chan A, Kim HK, Hsieh RK, Yu S, de Lima LG, Su WC, Banos A, Bhatia S, Burke TA, Keefe DMK (2014) Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice-a longitudinal analysis. Support Care Cancer 23(1):283–291. doi: 10.1007/s00520-014-2375-0 CrossRefPubMedGoogle Scholar
- 6.Molassiotis A, Lee P, Burke T, Dicato M, Gascon P, Roila F, Aapro M (2016) Anticipatory nausea, risk factors and its impact on chemotherapy-related nausea and vomiting: results from the PEER study. J Pain Symptom Manage in pressGoogle Scholar
- 7.Akechi T, Okuyama T, Endo C, Sagawa R, Uchida M, Nakaguchi T, Sakamoto M, Komatsu H, Ueda R, Wada M, Furukawa T (2010) Anticipatory nausea among ambulatory cancer patients undergoing chemotherapy: prevalence, associated factors, and impact on quality of life. Cancer Sci 101(12):2596–2600CrossRefPubMedGoogle Scholar
- 9.Molassiotis A, Aapro M, Dicato M, Gascon P, Novoa S, Isambert N, Burke T, Gu A, Roila F (2014) Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage 47(5):839–848. doi: 10.1016/j.jpainsymman.2013.06.012 CrossRefPubMedGoogle Scholar
- 13.Dupuis LL, Robinson PD, Boodhan S, Holdsworth M, Portwine C, Gibson P, Phillips R, Maan C, Stefin N, Sung L (2014) Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients. Pediatr Blood Cancer 61(8):1506–1512. doi: 10.1002/pbc.25063 CrossRefPubMedGoogle Scholar
- 14.Razavi D, Delvaux N, Farvacques C, De Brier F, Van Heer C, Kaufman L, Derde MP, Beauduin M, Piccart M (1993) Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam. J Clin Oncol 11(7):1384–1390PubMedGoogle Scholar
- 15.Raynov J, Stanchev R, Radinov A, Kancheva T (1999) Anticipatory emesis in cancer patients, treated with high - and moderately emetogenic chemotherapy. Arch Oncol 7(4):145–148Google Scholar
- 22.Morrow GR, Asbury R, Hammon S, Dobkin P, Caruso L, Pandya K, Rosenthal S (1992) Comparing the effectiveness of behavioral treatment for chemotherapy-induced nausea and vomiting when administered by oncologists, oncology nurses, and clinical psychologists. Health Psychol 11(4):250–256CrossRefPubMedGoogle Scholar